Answers are grounded in this paper and cite their sources.
Investigates the impact of comorbidity burden on cause-specific survival in large B-cell lymphoma, suggesting implications for treatment planning.
Chimeric antigen receptor T cell (CAR T) therapy has been transformative for patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) [1–3]. However, durable long-term remission in t...
No takes yet. Share an insight, caveat, or question.
Gong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: